Home LiteratureArticle Details
PMID: 8407287 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Thymosin beta 4 synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation.

Immunopharmacology ·Vol. 26 ·No. 1 ·1993-00-00 ·Pages 83-92

Moscinski LC, Naylor PH, Oliver J, Goldstein AL

Abstract

Recent evidence supports a role for thymosin beta 4 (T beta 4) in the inhibition of murine hematopoietic stem cell proliferation. This supposition results from studies in which the N-terminal tetrapeptide derived from native T beta 4 was administered to mice and appeared to prevent CFU-S recruitment into DNA synthesis. The importance of this observation was the concomitant ability of the tetrapeptide to prevent cytosine arabinoside (ara-C) toxicity in mice given LD50 doses of this drug. In the present study, we have extended these observations by demonstrating that whole synthetic T beta 4 is more effective than the N-terminal tetrapeptide in protecting mice from the toxicity of ara-C. This observation supports the hypothesis that T beta 4 is the biologically important parent molecule for this activity. To determine if inhibition of cell cycle progression also occurs in committed human bone marrow progenitors treated with T beta 4, we have investigated the effects of synthetic T beta 4 on proliferating and unstimulated enriched human bone marrow. In short-term liquid cultures studied sequentially over 1-7 days, T beta 4 failed to inhibit cell proliferation, but maintained the proliferative effect of granulocyte-macrophage colony stimulating factor (GM-CSF) on days following maximum stimulation (days 5-7). No effect was noted before the fifth day in culture, nor did T beta 4 exert any demonstrable effect in the absence of added GM-CSF. Any observable effect of T beta 4 required that it be present in the cultures on or before day 3 of GM-CSF stimulation. These results suggest that an additional effect of T beta 4 is the stimulation of a subpopulation of committed human bone marrow precursor cells to become more sensitive to the growth-promoting activity of GM-CSF, thereby enhancing myelopoiesis. It is of interest that the N-terminal peptide of T beta 4 is a shared sequence with tumor necrosis factor alpha, which is also known to have a similar stimulatory capacity. We, therefore, postulate that the growth enhancement noted in short-term cultures is mediated by the region containing these shared sequences.

MeSH Terms
Animals Bone Marrow/drug effects Bone Marrow Cells Cell Differentiation/drug effects Cell Division/drug effects Cells, Cultured Cytarabine/toxicity Drug Synergism Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology Hematopoietic Stem Cells/cytology,drug effects Humans Mice Recombinant Proteins/pharmacology Thymosin/pharmacology
Chemicals
Recombinant Proteins Cytarabine thymosin beta(4) Thymosin Granulocyte-Macrophage Colony-Stimulating Factor
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Moscinski L C
Department of Pathology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa 33682.
Naylor P H
Oliver J
Goldstein A L
Article Info
Journal
Immunopharmacology
Abbr.
Immunopharmacology
ISSN
0162-3109
Published
1993-00-00
Pages
83-92
Language
English
Region
Netherlands
NLM ID
7902474
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com